Article

Tocilizumab Inhibits Joint Damage Progression in RA

Interleukin-6 (IL-6) inhibition with tocilizumab (TCZ) plus methotrexate (MTX) retards joint damage progression independently of its impact on disease activity in patients with rheumatoid arthritis (RA).

Interleukin-6 (IL-6) inhibition with tocilizumab (TCZ) plus methotrexate (MTX) retards joint damage progression independently of its impact on disease activity in patients with rheumatoid arthritis (RA). Similar effects have been reported only for tumor necrosis factor (TNF) inhibitors, indicating that the effects of IL-6 inhibition on progression of joint damage in RA are among the most profound currently attainable.

Smolen and associates at the Medical University of Vi­enna used a random 90% sample of data from the TociLIz­umab Safety and THE Prevention of Structural Joint Damage (LITHE) study to compare the addition of placebo with the addition of TCZ every 4 weeks. They correlated baseline and 1-year values of clinical and serological variables with changes to 1 year of the total Genant-modified Sharp score (TGSS) using a Spearman test. Also, the progression of TGSS, erosion, and joint-space narrowing scores in groups that had low and high disease activity were compared for placebo and TCZ.

The change of TGSS was less in patients who received TCZ than in those who received placebo. In the latter patients, the correlation with TGSS change was significant for baseline scores of the Simplified Disease Activity Index (SDAI) and swollen joint count 28, with similar trends for C-reactive protein level. Similar correlations were seen for the SDAI, clinical disease activity index, and disease activity score 28 at 1 year, with radiographic changes during that year. None of the baseline or 1-year variables showed significant correlation with radiographic changes in patients who received TCZ plus MTX, suggesting a disassociation of the link between disease activity and damage by TCZ.

For patients in remission or with low disease activity, the progression of TGSS, erosion, and joint-space narrowing was similar among treatment groups; for those with moderate or high disease activity, progression was significantly greater in placebo-treated patients. The findings were reported in Annals of the Rheumatic Diseases.

Related Videos
Kimberly A. Davidow, MD: Elucidating Risk of Autoimmune Disease in Childhood Cancer Survivors
Matthew J. Budoff, MD: Examining the Interplay of Coronary Calcium and Osteoporosis | Image Credit: Lundquist Institute
Orrin Troum, MD: Accurately Imaging Gout With DECT Scanning
John Stone, MD, MPH: Continuing Progress With IgG4-Related Disease Research
Philip Conaghan, MBBS, PhD: Investigating NT3 Inhibition for Improving Osteoarthritis
Rheumatologists Recognize the Need to Create Pediatric Enthesitis Scoring Tool
Presence of Diffuse Cutaneous Disease Linked to Worse HRQOL in Systematic Sclerosis
Alexei Grom, MD: Exploring Safer Treatment Options for Refractory Macrophage Activation Syndrome
Jack Arnold, MBBS, clinical research fellow, University of Leeds, Leeds Institute of Rheumatic and Musculoskeletal Medicine
John Tesser, MD, Adjunct Assistant Professor of Medicine, Midwestern University, and Arizona College of Osteopathic Medicine, and Lecturer, University of Arizona Health Sciences Center, and Arizona Arthritis & Rheumatology Associates
© 2025 MJH Life Sciences

All rights reserved.